ArticleFrontiers in endocrinology2026
Sarcopenia index (serum creatinine/cystatin C ratio) independently identifies sarcopenia risk and mortality in older hospitalized patients with type 2 diabetes mellitus: a retrospective analysis.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia is increasingly recognized as a complication of type 2 diabetes mellitus (T2DM); however, simple screening tools for hospitalized older adults remain limited. The sarcopenia index (SI), calculated as serum creatinine (mg/dL)/cystatin C (mg/L) × 100, has been proposed as a readily available biomarker of muscle mass. However, its clinical utility and optimal cut-off value in older Chinese inpatients with T2DM are unclear. This retrospective study included 296 hospitalized older patients with T2DM from the Department of Geriatrics at Shanghai Sixth People's Hospital between July 2019 and April 2020 and evaluated all-cause mortality. Sarcopenia risk was diagnosed according to the Asian Working Group for Sarcopenia 2019 consensus criteria. Logistic regression was performed to assess the association between SI and sarcopenia risk. Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cut-off value, and Cox regression was used to evaluate the association between SI and mortality during follow-up (median 212 days). SI was significantly lower in patients with sarcopenia risk than in those without sarcopenia risk (68.0 ± 21.6 vs. 77.4 ± 20.0,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.